

References

I-137

1. Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. *N Engl J Med* 2014;370(12):1101-10.
2. Lee HZ, Miller BW, Kwitkowski VE et al. U.S. Food and Drug Administration Approval: Obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia. *Clin Cancer Res* 2014.
3. Radford J, Davies A, Cartron G et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). *Blood*.2013;122(7):1137-43.
4. Salles GA, Morschhauser F, Solal-Celigny P et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. *J Clin Oncol*. 2013;31(23):2920-6.
5. Morschhauser FA, Cartron G, Thieblemont C et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. *J Clin Oncol* 2013;31(23):2912-9.
6. National Comprehensive Cancer Network NCCN guidelines (version 2.2014).
7. Goede V, Engelke A, Fischer K, et al. Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. 2014;124 (21).
8. National Comprehensive Cancer Network NCCN guidelines (V2.2016).
9. Pott C, Belada D, Danesi N, et al. Analysis of Minimal Residual Disease in Follicular Lymphoma Patients in Gadolin, a Phase III Study of Obinutuzumab Plus Bendamustine Versus Bendamustine in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. *Blood*. 2015;126(23),3978.
10. MICROMEDEX®SOLUTIONS Compendia. 2017. Obinutuzumab.
11. Clinical Pharmacology Compendia. [database online]. Tampa FL: Gold Standard, Inc. Obinutuzumab.
12. NCCN Drugs & Biologics Compendium™. Obinutuzumab. 2017. National Comprehensive Cancer Network (NCCN).
13. Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. *N Engl J Med*. 2017;1331-44.
14. Vitolo U, Trneny M, Belada D, et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol*. 2017;3529-3537.
15. Grigg A, Dyer MJS, Diaz MG, et al. Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. *Haematologica*. 2017;765-772.
16. Delaware State Mandate; 18 DE Code, §§3338B and 3555B.